Compassionate Use/Expanded Access programs: Three steps to improve their implementation for the benefit of all
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.
Compassionate Use or Expanded Access is a treatment option for patients in desperate need which can be independently requested by a treating physician, providing access to locally unlicensed medications when all approved treatment options have been exhausted and enrollment in a clinical trial is not possible. There is no doubt about the human value of these programs for patients with no other option, and it’s also increasingly clear just how beneficial they can be for the entire health care ecosystem in addressing the unmet medical needs of patients. But many stakeholders, from governments, healthcare institutions to pharma companies, are not set up to make the best use of compassionate use. The time to change that is now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.